Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering
- 28 April 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 211, 104751
Abstract
No abstract availableKeywords
Funding Information
- Mount Royal University
This publication has 46 references indexed in Scilit:
- Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myelomaBiomedicine & Pharmacotherapy, 2023
- Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐TJournal of Biochemical and Molecular Toxicology, 2023
- CAR-T Therapies in Solid Tumors: Opportunities and ChallengesCurrent Oncology Reports, 2023
- Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyClinical Lymphoma Myeloma and Leukemia, 2022
- Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical PracticePharmaceutical Medicine, 2022
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- Therapeutic potential of CAR T cell in malignancies: A scoping reviewBiomedicine & Pharmacotherapy, 2022
- Quality of life in caregivers of patients receiving chimeric antigen receptor T‐cell therapyPsycho-Oncology, 2021
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Immuno-oncologic Approaches: CAR-T Cells and Checkpoint InhibitorsClinical Lymphoma Myeloma and Leukemia, 2017